Encouraged by the impressive clinical developments of CAR-T therapy in B cell malignancies, especially in CD19 CAR-T treating ALL [5, 6], the ligand-based anti-IL-10R CAR-T cells (IL-10 CAR-T) were developed. The gene discussed is IL10RA; the disease is acute lymphoblastic leukemia.